News
Wegovy maker Novo Nordisk CEO to step down
Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its weight-loss drugs and declining share price. Why it matters: Novo has faced challenges developing next-generation obesity drugs and will see its popular but pricey GLP-1s Ozempic and Wegovy subject to the next round of Medicare drug price negotiations in the U.
If child with a high BMI reaches a healthy weight by the age of six, they are no longer at risk of becoming obese later in ...
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s ...
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...
About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...
Queen Latifah opens up about obesity and heart health risks for public awareness campaign, Truth About Weight.
When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...
Overweight children are more vulnerable to early-onset hypertension. Childhood obesity is driving a rise in high blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback